BioMedNewsBreaks

ThursdaySep 21, 2023 3:16 pm

BioMedNewsBreaks – IBN’s BioMedWire Highlights NanoVibronix Inc.’s (NASDAQ: NAOV) $5M Private Placement

IBN, a multifaceted financial news and publishing company for private and public entities, has announced, through its biotech and biomed brand BioMedWire, the recent private placement offering for NanoVibronix (NASDAQ: NAOV), a medical device company that produces the UroShield(R), PainShield(R) and WoundShield(R) Surface Acoustic Wave (“SAW”) Portable Ultrasonic Therapeutic Devices. NanoVibronix in late August entered into definitive agreements for the purchase and sale of an aggregate of 2,906,977 shares of its common stock (or common stock equivalents in lieu thereof), series A-1 warrants to purchase up to 2,906,977 shares of common stock and series A-2 warrants to purchase up to…

Continue Reading

WednesdaySep 20, 2023 11:54 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Building Protection and Powerful IP Portfolio for Its Diabetes Gene Therapy Program

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced its entry into an exclusive license agreement related to a particular gene therapy for both type 1 and type 2 diabetes. “Specifically, the announcement involves a worldwide exclusive license to a patent application and related technology, and a worldwide non-exclusive license to use certain related know-how using the genes of the Pdx1 and MafA transcription factors controlled by a MafB promoter, as developed by the University of Pittsburgh. Genprex is developing technologies to administer disease-fighting genes that will provide…

Continue Reading

WednesdaySep 20, 2023 10:45 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Closes on $1.33M Registered Direct Offering

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, has closed on a registered direct offering of 1,146,552 of the company’s American Depositary Shares (“ADSs”). According to the announcement, each ADS represented four hundred ordinary shares offered at $1.16 per ADS (or ADS equivalent). The announcement noted that SCNI also issued unregistered warrants in a concurrent private placement comprised of up to 1,146,552 ADSs representing ordinary shares. The warrants have an exercise price of $1.16 per ADS and are immediately exercisable…

Continue Reading

TuesdaySep 19, 2023 12:55 pm

BioMedNewsBreaks – Datasea Inc. (NASDAQ: DTSS) Announces $2.0M Underwritten Public Offering

Datasea (NASDAQ: DTSS), a Nevada incorporated digital technology corporation engaged in converging and innovative business segments for intelligent acoustics and 5G messaging technology in China, recently announced the pricing of its underwritten public offering of 5,000,000 shares of common stock, each at a public offering price of $0.40, for aggregate gross proceeds of approximately $2.0 million. In addition, the company has granted the underwriters a 45-day option to purchase up to an additional 750,000 shares of common stock at the public offering price per share, less the underwriting discounts, to cover over-allotments, if any. Datasea intends to use the net…

Continue Reading

MondaySep 18, 2023 11:40 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Interim Results from FIH Clinical Trial of Lucid-MS

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announced the receipt of an interim report for the first-in-human (“FIH”) single ascending dose phase I clinical trial evaluating the company’s novel drug candidate. The interim blinded report for Lucid-21-302 (“Lucid-MS”), an orally administered treatment for multiple sclerosis ("MS"), was issued on Aug, 17, 2023, for the first four cohorts, with an addendum report describing the results of the fifth cohort due by the end of the month. “We are…

Continue Reading

FridaySep 15, 2023 1:04 pm

BioMedNewsBreaks — Why Renovaro BioSciences Inc. (NASDAQ: RENB) Is ‘One to Watch’

Renovaro BioSciences (NASDAQ: RENB), (formerly Enochian BioSciences Inc.), is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy. “Renovaro aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, as well as to potentially treat or cure serious infectious diseases… The oncology platform is now at the forefront of Renovaro’s development activities. While Renovaro’s current efforts focus primarily on pancreatic cancer, it plans to include other solid tumors with short life-expectancy in the first in human phase I/IIa studies that are on track to start by mid-2024,” reads a recent article. “Renovaro’s proprietary, novel…

Continue Reading

FridaySep 15, 2023 12:28 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Looks Forward to Acclaim-3 Trial on Heels of Receipt of FDA FTD and ODD Designations

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company recently announced that the United States Food and Drug Administration (“FDA”) had granted Orphan Drug Designation (“ODD”) to its lead drug candidate, REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid), for the treatment of small cell lung cancer (“SCLC”). The receipt of the ODD followed the FDA’s granting of Fast Track Designation (“FTD”) for REQORSA Immunogene Therapy in combination with Tecentriq in patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. “With…

Continue Reading

FridaySep 15, 2023 12:11 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Optimistic Berubicin May Provide Much-Needed Benefit for GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma (“GBM”) and neuro-oncology, recently presented updated safety results from its potentially pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin. “Most notably, this novel anthracycline demonstrated its capability to be a safe and innovative potential treatment option for GBM, having shown aspects integral to effective therapy for the disease… So far, 151 patients have been enrolled in the clinical study, with 105 set on Berubicin while the remaining 46 will be on Lomustine. This marks…

Continue Reading

FridaySep 15, 2023 11:59 am

BioMedNewsBreaks – Safety Shot (NASDAQ: SHOT) Rebrands with New Name, Ticker to Focus on New Business

Safety Shot (NASDAQ: SHOT), formerly known as Jupiter Wellness, has announced that effective today it has changed its name to Safety Shot; its ticker will also change to SHOT. The changes come after the company acquired Safety Shot, the first patented beverage that helps a person feel better faster by reducing blood alcohol content while also boosting clarity. The new beverage is currently being produced in the United States and will be available in the Q4 2023. Safety Shot is a patented beverage that helps to break down alcohol faster which aids in aiding in recovery and rehydration. Safety Shot is creating…

Continue Reading

FridaySep 15, 2023 11:48 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces $1.33M Registered Direct

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases. The company today announced its entry into a definitive agreement for the purchase and sale of 1,146,552 of the company’s American Depositary Shares (“ADSs”) (or ADS equivalents), each ADS representing 400 ordinary shares, at a purchase price of yesterday’s closing price of $1.16 per ADS (or ADS equivalent), in a registered direct offering. In addition, the company will issue unregistered warrants to purchase up to 1,146,552 ADSs representing ordinary shares…

Continue Reading